Personalized alcohol risk info tested to curb drinking in asian college students
NCT ID NCT07657221
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether giving Asian college students personalized information about their alcohol metabolism and genetic risks can influence their drinking habits. Researchers will follow 450 USC students of Chinese, Japanese, Korean, or Vietnamese heritage for two years. Participants provide DNA, complete surveys, and receive one of several brief online feedback sessions. The goal is to see if this approach can reduce risky drinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that personalized health risk feedback helps young adults make safer choices about alcohol.
- What could go wrong
- This is an early-stage behavioral study, not a treatment trial. It may not change drinking habits, and results may not apply to other groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL CONSUMPTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Southern California
Los Angeles, California, 90089, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test